Q3 2021

Filed Nov 4, 2021 · 10-Q · 35 days after period end · 0001558370-21-014650

Q3 2021 · 10-Q

Revenue

$12.10M

no prior Q3 2020 on file

Net Income

-$30.54M

N/M vs Q3 2020

EPS Diluted

-$0.44

N/M vs Q3 2020

Operating Income-$30,667,000N/M

Operating Cash Flow

Same quarter

Metric	Q3 2021	Q3 2020	Q3 2019	Q3 2018
Revenue	$12.10M	—	—	—
Net Income	-$30.54M	-$43.84M	-$27.06M	-$24.41M
EPS Diluted	-$0.44	-$0.66	-$0.49	-$0.51

The same fiscal quarter, prior years. Thaler holds no estimates to compare against.

Kiniksa Pharmaceuticals International, plc · CIK 1730430 · Engraved from SEC EDGAR